drugset / Trial / NCT03661632
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if BMS-986310 administered in combination with nivolumab, will demonstrate adequate safety and tolerability, as well as a favorable risk/benefit profile, to support further clinical testing.
Timeline
- Start
- 2018-09-11
- Primary completion
- 2019-11-11
- Completion
- 2020-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986310 | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |